Research and innovation
King’s Health Partners Cardiovascular aims to be global leaders in research and innovation to advance the prevention, early diagnosis and treatment of cardiovascular disease, though ground-breaking studies and a MedTech hub.
Our mission is to improve outcomes for patients with cardiovascular conditions through research-led discovery and innovation, including:
- Improved prevention, diagnosis and monitoring, through imaging, biomarkers, genetic risk, modelling and data science
- New therapies and therapeutic targets, through expertise in basic and translational cardiovascular science and experimental medicine
- Clinical innovation such as novel minimally-invasive procedures, novel devices, imaging-guided interventions and personalised treatment.
- More than 100 independent principal investigators including five British Heart Foundation Professors
- Current research grant income of over £114 million since 2014
- Since April 2014, Centre Principal Investigators have published more than 700 peer-reviewed papers.
King’s Health Partners Cardiovascular research activities are centred around the King's British Heart Foundation Centre of Research Excellence and the National Institute for Health Research Biomedical Research Centre.
The King's British Heart Foundation Centre was established through a national competition in 2008 and competitively renewed in 2014 and 2018. It has to date received the highest amount of funding of any UK British Heart Foundation Centre.
We provide specialist, research-lead cardiovascular services to an extensive population network.
We partner with many local and global organisations, including,
- international partnerships with major initiatives such as the Heart Centre Göttingen (Germany) and the University of Pennsylvania Division of Cardiovascular Medicine (USA)
- We also have many strategic partnerships with industry and pharma to enhance the translational potential of our research and drive clinical innovations.
Clinical trial highlights
CLEAR DVT: The goal of this initial proof of principle trial is to determine if contemporary endovascular venous intervention significantly reduces the two-year occurrence of Post Thrombotic Syndrome (PTS) in subjects with Deep Vein Thrombosis, compared to existing methods.
ARREST: This trial seeks to establish if expedited transfer to a heart attack centre with immediate coronary angiography (ICA), plus percutaneous coronary intervention, following an out-of-hospital cardiac arrest will confer a survival benefit compared to the current standard of care. The trial is run in collaboration with the London Ambulance Service and all London heart attack centres.
Prof Reza Razavi: advances in MRI-guided electrophysiology
Some of our recent highlights:
Interview with Prof Maura Giacca on the search for novel biological drugs for heart attack and heart failure.
The first Outcomes Book from King’s Health Partners Cardiovascular highlights the Institute’s progress, world-firsts in research, education strengths and how joined up working has made a positive impact on outcomes and patient care.
A new technology is currently being trialled to see if it can improve outcomes for the thousands of patients in the UK fitted with pacemakers.
New images have been captured using MRI which could revolutionise the diagnosis of congenital heart disease before babies are born.